Susquehanna Fundamental Investments LLC Takes Position in Emergent BioSolutions Inc. (NYSE:EBS)

Susquehanna Fundamental Investments LLC purchased a new stake in shares of Emergent BioSolutions Inc. (NYSE:EBS - Free Report) during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 118,647 shares of the biopharmaceutical company's stock, valued at approximately $300,000. Susquehanna Fundamental Investments LLC owned 0.23% of Emergent BioSolutions as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Charles Schwab Investment Management Inc. increased its position in shares of Emergent BioSolutions by 84.1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 2,873,984 shares of the biopharmaceutical company's stock worth $6,898,000 after purchasing an additional 1,312,934 shares during the last quarter. Assenagon Asset Management S.A. boosted its stake in Emergent BioSolutions by 356.2% in the fourth quarter. Assenagon Asset Management S.A. now owns 834,372 shares of the biopharmaceutical company's stock worth $2,002,000 after buying an additional 651,480 shares in the last quarter. Dynamic Technology Lab Private Ltd purchased a new stake in Emergent BioSolutions in the fourth quarter worth approximately $232,000. CoreCap Advisors LLC purchased a new stake in Emergent BioSolutions in the fourth quarter worth approximately $33,000. Finally, SG Americas Securities LLC boosted its stake in Emergent BioSolutions by 171.7% in the fourth quarter. SG Americas Securities LLC now owns 66,011 shares of the biopharmaceutical company's stock worth $158,000 after buying an additional 41,712 shares in the last quarter. 78.40% of the stock is currently owned by institutional investors.

Insider Activity

In other news, Director Kathryn C. Zoon sold 10,000 shares of the stock in a transaction that occurred on Tuesday, June 4th. The stock was sold at an average price of $6.11, for a total transaction of $61,100.00. Following the completion of the sale, the director now owns 54,482 shares of the company's stock, valued at $332,885.02. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Over the last 90 days, insiders sold 12,919 shares of company stock valued at $75,831. 1.20% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Separately, Benchmark reaffirmed a "buy" rating and issued a $8.00 target price on shares of Emergent BioSolutions in a research note on Tuesday, July 2nd.

Emergent BioSolutions Price Performance

EBS traded down $0.08 during midday trading on Wednesday, hitting $12.03. The stock had a trading volume of 3,403,392 shares, compared to its average volume of 3,898,353. The company has a market cap of $630.40 million, a P/E ratio of -1.09 and a beta of 1.62. The business has a fifty day moving average of $6.67 and a 200 day moving average of $3.83. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.55 and a current ratio of 1.08. Emergent BioSolutions Inc. has a 1 year low of $1.42 and a 1 year high of $12.74.

Emergent BioSolutions (NYSE:EBS - Get Free Report) last released its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.59 earnings per share for the quarter, beating analysts' consensus estimates of ($3.65) by $4.24. The firm had revenue of $300.40 million during the quarter. Emergent BioSolutions had a negative return on equity of 18.53% and a negative net margin of 47.68%. During the same period last year, the company posted ($3.17) EPS. As a group, equities analysts forecast that Emergent BioSolutions Inc. will post -1.98 earnings per share for the current fiscal year.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.